Nasdaq IPOs

KKR Acquisition Holdings I, a blank check company formed by KKR and former Gap CEO Glenn Murphy targeting the consumer sector, filed on Thursday with the SEC to raise up to $1.0 billion in an initial public offering. The New York, NY-based company plans to raise $1.0 billion by

ArcLight Clean Transition II, the second blank check company formed by ArcLight Capital Partners targeting renewables, filed on Thursday with the SEC to raise up to $250 million in an initial public offering. The Boston, MA-based company plans to raise $250 million by offering 2

Northern Star Investment IV, the fourth blank check company formed by Joanna Coles and SPAC veteran Jonathan Ledecky, filed on Thursday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans to raise $300 million by offering

Northern Star Investment III, the third blank check company formed by Joanna Coles and SPAC veteran Jonathan Ledecky, filed on Thursday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans to raise $300 million by offering

Slam Corp., a blank check company led by former professional baseball player Alex Rodriguez, filed on Thursday with the SEC to raise up to $500 million in an initial public offering. The New York, NY-based company plans to raise $500 million by offering 50 million units at $10.

First Reserve Sustainable Growth, a blank check company formed by First Reserve targeting sustainability, filed on Thursday with the SEC to raise up to $200 million in an initial public offering. The Stamford, CT-based company plans to raise $200 million by offering 20 million u

Apollo Strategic Growth Capital II, the second blank check company formed by Apollo targeting growth-oriented businesses, raised the proposed deal size for its upcoming IPO on Thursday. The New York, NY-based company now plans to raise $500 million by offering 50 million units a

Bioventus, which offers orthobiologics products for musculoskeletal conditions, announced terms for its IPO on Thursday. The company had previously filed to raise $150 million at a $575 million market cap in July 2016, but withdrew the offering the following August. The Dur

Decarbonization Plus Acquisition II, the fourth blank check company formed by Riverstone targeting businesses advancing global decarbonization, raised $350 million by offering 35 million units at $10. Each unit consists of one share of common stock and one-third of a warrant

Itiquira Acquisition, a blank check company targeting growth sectors in Brazil, raised $200 million by offering 20 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50. SPX Equities Gestão de Recur

Centricus Acquisition, a UK-based blank check company led by former executives at Silversea Cruises and Deutsche Bank, raised $300 million by offering 30 million units at $10. The company offered 5 million more units than anticipated. Each unit consists of one share of common sto

Astrea Acquisition, a blank check company targeting the hospitality and financial services sectors, raised $150 million by offering 15 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50. The company is led

Novus Capital Corp II, a blank check company targeting businesses enabling smart technology evolution, raised $250 million by offering 25 million units at $10. Each unit consists of one share of common stock and one-third of a warrant, exercisable at $11.50. The company is

Atlas Crest Investment II, the second blank check company formed by Moelis and Company, raised $300 million by offering 30 million units at $10. The company offered 5 million more units than anticipated. Each unit consists of one share of common stock and one-fourth of a war

Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, raised $100 million by offering 6.3 million shares at $16, within the range of $15 to $17. At pricing, the company commands a fully diluted market value of $650 million. The com

Atotech, a Carlyle-backed specialty chemicals company carved out of Total, raised $498 million by offering 29.3 million shares at $17, below the range of $19 to $22. The selling shareholders did not offer shares on the IPO, but will sell on the overallotment if it is exercised.

Sana Biotechnology, a preclinical biotech developing engineered cell therapies for multiple indications, raised $588 million by offering 23.5 million shares at $25, above upwardly revised the range of $23 to $24. The company offered 1.5 million more shares than anticipated. It or

Sensei Biotherapeutics, a Phase 2 biotech developing bacteriophage-based therapies for cancer, raised $133 million by offering 7 million shares at $19, above the range of $16 to $18. The company offered 1.1 million more shares than anticipated. Sensei's proprietary ImmunoPhage p

Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise $194 million by offering 10.5 million shares at a price range of $18 t

Longeveron, a Phase 2 biotech developing cellular therapies for aging-related conditions, announced terms for its IPO on Wednesday. The Miami, FL-based company plans to raise $25 million by offering 2.3 million shares at a price range of $10 to $12. At the midpoint of the propos